Navigation Links
Five-Year Data Confirm That Early Treatment with Betaseron(R) at First Sign of Disease Can Delay Progression to MS
Date:9/20/2008

- BENEFIT is first and only prospectively planned 5-year study to show long

lasting benefit of early treatment -

MONTREAL, Sept. 20 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals announced today that new data from its BENEFIT (BEtaseron in Newly Emerging multiple sclerosis For Initial Treatment) study confirm that early initiation of Betaseron(R) (interferon beta-1b) treatment in patients with a first event suggestive of multiple sclerosis (MS) significantly delayed the onset of clinically-definite MS (CDMS) by 37 percent (p=0.003) and McDonald MS by 45 percent (p<0.0001) over five years compared to delayed treatment. The results confirm a continued benefit of initiating treatment with Betaseron shortly after the first event.(1) These five-year findings from the BENEFIT study were presented today at the World Congress on Treatment and Research in Multiple Sclerosis (WCTRIMS).

"The BENEFIT five-year results are the first and only prospectively planned data to confirm a continuous benefit over five years when treatment is initiated shortly after the earliest sign of MS," said Dr. Mark Freedman, Professor of Neurology at the University of Ottawa and investigator of the study. "These results confirm that treatment with Betaseron after the first MS event or attack can reduce the risk of developing MS over five years compared to delayed treatment."

The study also demonstrated that early treatment with Betaseron had a beneficial effect on cognition that became even more pronounced over time. At five years, patients with early treatment had better cognitive function (mean PASAT score) compared to patients with delayed treatment (p= 0.0045).(1) PASAT, or the Paced Auditory Serial Addition Test, is a widely accepted tool that measures intellectual function and cognition.

"Changes in cognitive function have important implications for a patient's quality of life. Changes in cognition, along with fatigue, can be a reason for
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
2. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
3. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
4. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
5. Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
6. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
7. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
8. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
9. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
10. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
11. IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014  ResMed Inc. (NYSE: RMD ) ... fiscal year ended June 30, 2014.  Revenue for the quarter ... 30, 2013 (a 1 percent decrease on a constant currency ... percent compared to the quarter ended June 30, 2013. Diluted ... of 22 percent compared to the quarter ended June 30, ...
(Date:7/31/2014)... , July 31, 2014  Cepheid (NASDAQ: ... at the following conferences, and invited investors to participate via ... Conference, New York, NY Wednesday, August ... Baird Health Care Conference, New York, NY ... , Accessing Live Webcasts To access the live ...
(Date:7/31/2014)... Conn. , July 31, 2014  UBM Medica ... a leading online community for oncologists, presents exclusive slide ... that are essential to quality cancer care. ... journal ONCOLOGY , offers news, blogs, and podcasts ... for oncologists highlighting quality cancer care: , End-of-life ...
Breaking Medicine Technology:RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Cepheid to Webcast Upcoming Financial Presentations 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3
(Date:8/1/2014)... New York (PRWEB) August 01, 2014 ... ) on behalf of women who allegedly experienced the ... power morcellators in gynecological surgeries, Bernstein Liebhard LLP notes ... withdraw a number of power morcellators marketed by its ... report from The New York Times, some critics of ...
(Date:8/1/2014)... Rochelle, NY, August 1, 2014Lesbian, gay, bisexual, and transgender ... the same problems as some of their heterosexual and ... they often face additional physiological and legal challenges ... recent advances in assisted reproduction options is presented in ... Future Possibilities ," published in LGBT Health ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Market ... research reports have been added to its catalogue. ... Active Pharmaceutical Ingredients (APIs), Contract Research and Manufacturing ... key pharma industry drivers include, among others, increasing ... personal hygiene. In 2015, the pharma market in ...
(Date:8/1/2014)... FRIDAY, Aug. 1, 2014 (HealthDay News) -- Patients with ... pulmonary disease (COPD) have a new weapon to battle ... Thursday. The agency approved a new treatment, ... the third leading killer of Americans. COPD, which is ... as chronic bronchitis and emphysema. Patients with ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 The North ... endpoint security solutions market in North America with analysis ... grow from around $3.53 billion in 2014 to $4.77 ... 2014 to 2019. , Browse through the TOC of ... an idea of the in-depth analysis provided. It also ...
Breaking Medicine News(10 mins):Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 4Health News:Advances in assisted reproduction create more options and new legal issues for LGBT couples 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 3Health News:FDA Approves New Treatment for People With COPD 2Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 4
... promote cancer screening by announcing that only one in five ... to have an examination. But a new study published in ... Psychological Science, finds that this well-meaning message has the exact ... get screened. In an earlier study, Monika Sieverding ...
... HealthDay Reporter , MONDAY, July 26 (HealthDay News) ... the clot-dissolving drug tPA from 3 hours to up to ... any significant delays in treatment and appears to be a ... there was a slight increased risk of death and bleeding ...
... , MONDAY, July 26 (HealthDay News) -- Too many ... prostate-specific antigen (PSA) is normal or below normal, still ... evidence has shown that among older men with low-risk ... but another condition. For these men, watchful waiting is ...
... studies that compares two treatments for preventing strokes due carotid artery ... UT Southwestern Medical Center physician reports in an editorial in today,s ... "The most recent data on treatment options for carotid artery disease ... Dr. Ethan Halm, chief of the William T. and Gay F. ...
... Reporter , MONDAY, July 26 (HealthDay News) -- Doctors across ... open up clogged neck arteries to help prevent stroke, a ... fills up major arteries supplying blood to the brain, greatly ... the condition: an artery-scraping surgery called endarterectomy; the placement of ...
... cancer survival is associated with increased risk of long-term ... the July 26 issue of Archives of Internal ... to background in the article, childhood cancer survival rates ... roughly 70 to 80 percent currently. The authors also ...
Cached Medicine News:Health News:Few people are doing it, so why should I? Motivating men to seek cancer screening 2Health News:Longer Time Frame for Clot-Busting Drug May Help Beat Stroke 2Health News:Longer Time Frame for Clot-Busting Drug May Help Beat Stroke 3Health News:Most Men With Low-Risk Prostate Cancer Treated Aggressively, Study Shows 2Health News:Most Men With Low-Risk Prostate Cancer Treated Aggressively, Study Shows 3Health News:Surgery or stenting for carotid artery disease? Question remains 2Health News:Surgery or stenting for carotid artery disease? Question remains 3Health News:Stroke Prevention Treatment Varies Widely Across U.S. 2Health News:Stroke Prevention Treatment Varies Widely Across U.S. 3Health News:Stroke Prevention Treatment Varies Widely Across U.S. 4Health News:Childhood cancer survivors may have abnormal long-term cardiac function 2
... can be difficult for persons who have ... cord injuries and for children with poor ... other motor or coordination problems. The FoamWrap ... and coordination. Soft foam-lined material provides light ...
... a low profile contour at the palmar crease ... is an excellent choice to treat mild to ... or for wear following cast removal. The ... pile cinch fasteners provides support and compression to ...
... to treat DeQuervain's Tendonitis, strains and sprains ... advanced carpal tunnel syndrome and cumulative trauma ... Distal palmar crease contour allows for 90 ... Constructed from an open cell urethane ...
... is a solid, one-piece custom wrist orthotic designed to ... , ,Indications: , Wrist reconstruction , ... , Coles fracture - distal radius , ... , ORIF - Open reduction and internal ...
Medicine Products: